ocr-ner-001-b:
  cases:
    - ocr-ner-001-b.v0
  description: >
    Evaluation for OCR/NER extraction on Case ocr-ner-001-b.
    This evaluation verifies that the system correctly handles slight variations in the extracted data.
  disclaimer: >
    Evaluations are performed zero-shot without additional fine-tuning.

ocr-ner-001-b.v0:
  class: src.evals.custom.ocr_ner_evaluator:OCRNEREvaluator
  args:
    similarity_threshold: 95.0
    uploaded_files: "utils/data/cases/001/b"
    expected_output:
      ocr_ner_results:
        patient_info:
          patient_name: "Sarah Sample"
          patient_date_of_birth: "10/19/2014"
          patient_id: "4567890"
          patient_address: "28 W Comet Ave, Chicago, IL 60607"
          patient_phone_number: "555-123-4567"
        physician_info:
          physician_name: "Shiva Pedram, MD"
          specialty: "Pediatrics"
          physician_contact:
            office_phone: "555-991-2750"
            fax: "555-786-5643"
            office_address: "5721 S Maryland Ave, Chicago, IL 60637"
        clinical_info:
          diagnosis: "Crohn's Disease; Anemia 2/2 blood loss"
          icd_10_code: "K50.90; D50.9"
          prior_treatments_and_results: "Not provided"
          specific_drugs_taken_and_failures: "Not provided"
          alternative_drugs_required: "Not provided"
          relevant_lab_results_or_imaging: >
            Hemoglobin: 9.0 g/dL (11.5 - 15.5 g/dL); Hematocrit: 32% (34.5% - 44.5%);
            Red Blood Cells (RBC): 3.5 million/µL (4.0 - 5.5 million/µL); Mean Corpuscular Volume (MCV): 78 fL (80 - 100 fL);
            Mean Corpuscular Hemoglobin (MCH): 28 pg (27 - 31 pg); Mean Corpuscular Hemoglobin Concentration (MCHC): 34 g/dL (32 - 36 g/dL);
            Platelets: 450,000 cells/µL (150,000 - 400,000 cells/µL); White Blood Cells (WBC): 12,000 cells/µL (4,500 - 13,500 cells/µL);
            Bands (Immature Neutrophils): 5% (0 - 5%); Neutrophils: 75% (40 - 70%); Lymphocytes: 18% (20 - 50%);
            Monocytes: 4% (2 - 8%); Eosinophils: 1% (0 - 5%); Basophils: 0% (0 - 1%); Glucose: 90 mg/dL (70 - 100 mg/dL);
            BUN: 15 mg/dL (7 - 20 mg/dL); Creatinine: 0.5 mg/dL (0.3 - 0.7 mg/dL); Sodium: 138 mEq/L (135 - 145 mEq/L);
            Potassium: 4.0 mEq/L (3.5 - 5.0 mEq/L); Chloride: 102 mEq/L (98 - 107 mEq/L); Bicarbonate: 24 mEq/L (22 - 30 mEq/L);
            Calcium: 9.2 mg/dL (8.5 - 10.5 mg/dL); ESR: 15 mm/h (<20 mm/h); CRP: 12 mg/L (<5 mg/L);
            Fecal Calprotectin: 100 µg/g (<50 µg/g); Fecal Occult Blood: Positive (Negative);
            AST: 25 U/L (10 - 40 U/L); ALT: 22 U/L (7 - 56 U/L); ALP: 120 U/L (40 - 150 U/L);
            Bilirubin (Total): 0.6 mg/dL (0.1 - 1.2 mg/dL); Ferritin: 15 ng/mL (12 - 150 ng/mL);
            Iron: 40 µg/dL (50 - 150 µg/dL); Total Iron Binding Capacity (TIBC): 450 µg/dL (250 - 450 µg/dL);
            Folate Level: 5 ng/mL (4 - 20 ng/mL); Vitamin B12 Level: 300 pg/mL (200 - 900 pg/mL);
            EGD Findings: Biopsies obtained and pending; Esophagus: Normal appearance;
            Stomach: Gastritis, erythema present; Duodenum: Mild to moderate duodenitis with edema;
            Colonoscopy Findings: Biopsies obtained and pending; Ileum: Patchy inflammation with areas of erythema and ulceration;
            Colon: Diffuse inflammation. Granularity and friability present; Rectum: Mild inflammation; no significant ulceration;
            MRI enterography: pending
          symptom_severity_and_impact: >
            Patient has multiple episodes of abdominal cramping and bowel movements with visible hematochezia;
            Patient appears pale, tired but interactive; Positive for fatigue, pallor, abdominal pain, hematochezia, dizziness, blood loss (by rectum);
            HR 110 bpm; BP 110/70 mmHg; RR: 20 bpm; Temp: 98.6°F (37°C); Mild tachycardia present; Pallor present
          prognosis_and_risk_if_not_approved: >
            Continues to have frequent blood in stools and anemia as well as abdominal discomfort
          clinical_rationale_for_urgency: >
            Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)
          treatment_request:
            name_of_medication_or_procedure: "Adalimumab"
            code_of_medication_or_procedure: "Not provided"
            dosage: >
              160 mg (given as four 40 mg injections on day 1) followed by 80 mg (given as two 40 mg injections) two weeks later.
              40 mg every other week starting 2 weeks from 2nd dose.
            duration: "6 months; 16 injections"
            rationale: "Patient will likely need to initiate biologic therapy given severity of symptoms"
            presumed_eligibility: "Not provided"